crovalimab (Piasky)
Jump to navigation
Jump to search
Indications
* adults & childen >= 40 kg (88 lbs)
Dosage
- meningococcal vaccination prior to 1st dose
- after a series of loading doses,
- maintenance: subcutaneous injection every 4 weeks.
- dosage is weight-dependent, refer to Highlights of Prescribing Information[2]
Adverse effects
- infusion-related reactions
- infections (respiratory tract infections & viral infectionz)
- Type 3 hypersensitivity reactions
- boxed warning:
- life-threatening infections caused by Neisseria meningitidis
Mechanism of action
- complement C5 inhibitor
- engineered to be recycled in the bloodstream to sustain responses
More general terms
References
- ↑ Ingram I Subcutaneous C5 Inhibitor Approved for PNH. Longer-acting crovalimab designed for more sustained effect and less treatment burden. MedPage Today June 24, 2024 https://www.medpagetoday.com/hematologyoncology/hematology/110793
- ↑ 2.0 2.1 Highlights of Prescribing Information* PIASKY (crovalimab-akkz) injection, for intravenous or subcutaneous use https://www.gene.com/download/pdf/piasky_prescribing.pdf